https://medicinova.com/corporate/mnov-abstract-on-mn-166-to-be-presented-at-als-mnd-international-symposium/2019-08-14T11:16:35+09:00https://medicinova.com/corporate/mnov-phase-3-trial-initiated-for-mn-166-in-als/2019-10-30T11:40:08+09:00https://medicinova.com/corporate/mnov-multiple-trials-of-mn-166-ongoing-recent-price-move-creates-buying-opportunity/2020-02-25T11:42:51+09:00https://medicinova.com/corporate/mnov-mn-166-to-be-developed-as-a-treatment-for-severe-pneumonia-and-acute-respiratory-distress-syndrome/2020-03-12T11:47:09+09:00https://medicinova.com/corporate/mnov-multiple-shots-on-goal-provide-substantial-potential-upside/2020-05-01T11:49:08+09:00https://medicinova.com/corporate/mnov-fda-gives-ok-to-initiate-clinical-trial-of-mn-166-to-prevent-ards-in-covid-19-patients/2025-10-16T11:52:07+09:00https://medicinova.com/corporate/mnov-20m-investment-to-fund-multiple-programs/2025-10-16T11:54:52+09:00https://medicinova.com/corporate/mnov-barda-contract-to-support-development-of-mn-166-in-ards/2025-10-16T11:57:28+09:00https://medicinova.com/corporate/mnov-milestone-payments-from-legacy-gene-therapy-assets/2025-10-16T12:00:50+09:00https://medicinova.com/corporate/mnov-phase-3-als-trial-ongoing/2025-10-16T12:02:45+09:00https://medicinova.com/corporate/mnov-positive-results-for-mn-166-in-phase-2-aud-trial/2025-10-16T12:04:10+09:00https://medicinova.com/corporate/mnov-animal-trials-commence-testing-mn-166-as-an-mcm/2025-10-16T12:24:15+09:00https://medicinova.com/corporate/mnov-addition-of-mn-166-to-pd-1-treatment-extends-survival-in-preclinical-gbm-model/2025-10-16T12:10:58+09:00https://medicinova.com/corporate/mnov-ibudilast-identified-as-promising-development-candidate-in-alcohol-use-disorder-and-degenerative-cervical-myelopathy/2025-10-16T12:12:54+09:00https://medicinova.com/corporate/mnov-genzyme-patent-litigation-could-lead-to-significant-payout/2025-10-16T13:50:43+09:00https://medicinova.com/corporate/mnov-plans-for-phase-2-study-of-mn-001-tipelukast-in-nafld-patients-with-type-2-diabetes-and-hypertriglyceridemia/2025-10-16T12:16:18+09:00https://medicinova.com/corporate/mnov-positive-results-for-mn-166-ibudilast-in-patients-at-risk-of-acute-respiratory-distress-syndrome/2025-10-16T13:53:08+09:00https://medicinova.com/corporate/mnov-phase-2-trial-of-mn-001-in-nafld-patients-with-type-2-diabetes-and-hypertriglyceridemia-underway/2025-10-16T13:54:46+09:00https://medicinova.com/corporate/mnov-well-financed-to-get-through-tough-market-conditions/2025-10-16T13:57:02+09:00https://medicinova.com/corporate/mnov-phase-1-2-clinical-trial-of-mn-166-in-gbm-fully-enrolled/2025-10-16T13:58:29+09:00https://medicinova.com/corporate/mnov-compelling-buying-opportunity-in-differentiated-small-cap-biotech/2025-10-16T14:01:02+09:00https://medicinova.com/corporate/mnov-expecting-data-for-mn-166-in-gbm-and-chlorine-gas-induced-lung-injury/2025-10-16T14:02:54+09:00https://medicinova.com/corporate/mnov-positive-results-for-mn-166-in-chlorine-gas-induced-acute-lung-injury-model/2025-10-16T14:04:42+09:00https://medicinova.com/corporate/mnov-encouraging-phase-2-glioblastoma-results-presented-at-sno/2025-10-16T14:06:07+09:00https://medicinova.com/corporate/mnov-capital-efficient-model-and-large-late-stage-pipeline-makes-medicinova-stand-out-among-peers/2025-10-16T14:08:06+09:00https://medicinova.com/corporate/medicinova-corporate-presentation/2025-10-16T14:09:46+09:00